How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics
Jonathan Sporn (CEO + Founder of Gilgamesh Pharma) joins for a deep dive into next-gen psychedelic medicines, why duration matters for real-world clinical use, and more.
External link. We are not responsible for the content.
Read more βMore From PsyMed Ventures
Brain Organoids: from Space to AI with Alysson Muotri
Professor Alysson R. Muotri (geneticist and developmental biologist at UC San Diego) joins for a far out conversation...
Digital Addiction: The Investment Landscape + What Wins Now
The first thing many of us touch in the morning is a screen. Checking notifications quickly turns into a scroll, the ...
The Future of Whole Brain Emulation
Whole brain emulation without the sci-fi, by PsyMedβs Danny Carbonero
Latest News
What Do Psychedelics Want From Us?
Welcome to the Psychedelic Blog. I write about the impact of Psychedelics on Grieving, Relationships, Culture & Death.
Dads Are Tripping and Itβs Making Them Better Fathers
Here's what can happen when dads stop performing and start feeling. [...] Read More... The post Dads Are Tripping and...
Medical Psilocybin Act
New York lawmakers are officially considering the βMedical Psilocybin Act,β legislation that would create legal acces...
Is New York About to Become a Medical Psilocybin Pioneer?
The bill just needs to reach the floor...and the clock is ticking. [...] Read More... The post Is New York About to B...
Are Some Drugs Really More Criminal or Just More Policed?
PLUS stories about psychedelic assisted therapy for journalists, psychedelic dioramas, and a 5-MeO-DMT workshop you d...
The Fragmented Self: On Psychedelics, Trauma, and Alienation
The self was never as unified as we assume, and psychedelics β by dissolving its boundaries β can fragment it further...